The Journal's Policy on Cost-Effectiveness Analyses
Open Access
- 8 September 1994
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (10), 669-670
- https://doi.org/10.1056/nejm199409083311009
Abstract
Concern about cost now dominates many decisions about the use of drugs and other therapeutic interventions. Increasingly, such decisions are being influenced by published economic analyses that relate the effectiveness of treatments and their associated costs (cost-effectiveness analyses). Many of these analyses are supported by grants from the National Institutes of Health (NIH) or other neutral sources. Some, however, are funded by companies that hope these analyses will put their products in a favorable light1. Companies might then even use particularly favorable analyses to justify the prices of new drugs.Keywords
This publication has 5 references indexed in Scilit:
- Understanding Financial Conflicts of InterestNew England Journal of Medicine, 1993
- Financial Conflicts of Interest in Biomedical ResearchNew England Journal of Medicine, 1993
- Avoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical CompaniesNew England Journal of Medicine, 1991
- New Information for Authors — And ReadersNew England Journal of Medicine, 1990
- Dealing with Conflicts of InterestNew England Journal of Medicine, 1984